TRex Bio Q3 2026 Results: Net Loss of $13.2M, Loss Widens
TRex Bio, Inc. is a clinical-stage biopharmaceutical company that has incurred substantial losses since inception and expects these losses to increase as it develops its autoimmune and inflammatory disease product candidates. As of November 5, 2026, the company had 28,788,654 shares of common stock outstanding and is classified as an emerging growth company.
- Key figure
- Net loss $13.2M